Net sales declined year-over-year, but cost reductions improved quarterly results. Growth hinges on Kardium's US launch, with strong clinical data and new funding supporting expansion. The company is diversifying its customer base to reduce risk and drive future revenue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.